Akums introduces Hydroxyurea oral suspension for sickle cell disease
2024-03-18
细胞疗法上市批准免疫疗法
Preview
来源: Pharmaceutical Technology
Akums’ new medicine will be sold for sickle cell disease treatment. Credit: kikpokemon / Shutterstock.com.
Indian company Akums Drugs and Pharmaceuticals has introduced Hydroxyurea oral suspension, the country’s first room temperature-stable drug for treating sickle cell disease, according to a LinkedIn post.
The new formulation offers a cost-effective alternative to imported brands in the country.
Designed for ease of use across all age groups suffering from sickle cell disease, Hydroxyurea oral suspension will be offered as oral syringes to guarantee precise dosage, enhancing patient compliance and treatment efficacy.
The existing imported Hydroxyurea solution, which requires refrigeration between 2°C and 8°C, costs Rs77,000 ($928.9) in the Indian market.
Akums’ novel oral suspension drug will be available for Rs600, making it highly accessible to patients.
See Also:
With FDA greenlight, BMS Breyanzi brings CAR-T cell therapy to CLL and SLL
Preview
来源: Pharmaceutical Technology
AstraZeneca snaps up Amolyt for $1.05bn to boost rare disease pipeline
Preview
来源: Pharmaceutical Technology
An inherited blood ailment, sickle cell disease changes the red blood cells into a sickle shape, which hampers their ability to transport oxygen across the body effectively.
Hydroxyurea aids red blood cells to maintain a rounder and larger shape, allowing for improved oxygen delivery throughout the body.
In a media statement posted on LinkedIn, Akums Drugs and Pharmaceuticals said: “In alignment with the objectives outlined in the national sickle cell anaemia mission, as announced by the Honourable Prime Minister Shri Narendra Modi Ji, Akums pledges to provide this medicine to the government at less than 1% of the cost of global brand imported in India, thus embodying the spirit of ‘Make in India’ and fostering widespread benefit to the masses.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。